Page last updated: 2024-12-06

diaziquone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diaziquone is an experimental anticancer drug that acts as an alkylating agent. It was initially synthesized in the 1970s and has shown promising activity against a variety of cancers, particularly leukemia. Diaziquone works by binding to DNA and preventing its replication, leading to cell death. Research on diaziquone has focused on its potential to treat refractory leukemia and other hematological malignancies. While it showed early promise, clinical trials were ultimately discontinued due to its significant side effects, such as bone marrow suppression and neurotoxicity. Despite its discontinued clinical development, diaziquone continues to be studied in preclinical settings for its potential use in combination therapies or in new drug formulations that mitigate its toxicity.'

diaziquone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID42616
CHEMBL ID36016
CHEBI ID90185
SCHEMBL ID4975
MeSH IDM0093095

Synonyms (57)

Synonym
carbamic acid,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]bis-, diethyl ester
nsc 182986
nsc-182986
1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester
azq ,
57998-68-2
NSC182986 ,
diaziquone
aziridinyl benzoquinone
NCIMECH_000556
NCI60_001523
ci-904
3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone
1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester
carbamic acid, (2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadien-1,4-diyl)bis-,diethyl ester
diethyl 2,5-bis-(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamate
aziridinylbenzoquinone
diaziquonum [inn-latin]
brn 1333277
aziridinylquinone
carbamic acid, (2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl)bis-, diethyl ester
diaziquone [usan:inn]
3,6-bis(carboxyamino)-2,5-diaziridinyl-1,4-benzoquinone
diaziquona [inn-spanish]
ci 904
2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone
D03774
diaziquone (usan/inn)
PRESTWICK_54
ethyl n-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxo-cyclohexa-1,4-dien-1-yl]carbamate
2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid, diethyl ester
CHEMBL36016
chebi:90185 ,
ethyl n-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate
CCG-35937
fql5eup13w ,
unii-fql5eup13w
diaziquona
diaziquonum
5-20-01-00072 (beilstein handbook reference)
SCHEMBL4975
diaziquone [mi]
diaziquone [mart.]
diaziquone [usan]
diaziquone [who-dd]
diaziquone [inn]
WVYXNIXAMZOZFK-UHFFFAOYSA-N
[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]bis-carbamicacid diethyl ester
nsc 182968
3,6-diaziridinyl-2,5-bis(ethoxycarbonylamino)-1,4-benzoquinone
diazicuona
diethyl [2,5-bis(aziridin-1-yl)-3,6-dioxocyclohexa-1,4-diene-1,4-diyl]biscarbamate
DTXSID40206721
Q27162386
diethyl (2,5-di(aziridin-1-yl)-3,6-dioxocyclohexa-1,4-diene-1,4-diyl)dicarbamate
CS-0078849
HY-119969

Research Excerpts

Overview

Diaziquone is an aziridinylbenzoquinone with properties suggestive of an alkylating agent. Diaziquone (AZQ) is a substrate for this NAD(P)H oxidoreductase active S9 fraction as judged by its enzymatic reduction detected spectrophotometrically.

ExcerptReferenceRelevance
"Diaziquone is an aziridinylbenzoquinone with properties suggestive of an alkylating agent. "( Diaziquone (AZQ).
Bender, JF; Grillo-Lopez, AJ; Posada, JG, 1983
)
3.15
"Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. "( Phase I trial of diaziquone (AZQ) plus GM-CSF.
Ames, MM; Hartmann, LC; Reid, JM; Richardson, RL, 1995
)
2.07
"Diaziquone (AZQ) is a substrate for this NAD(P)H oxidoreductase active S9 fraction as judged by its enzymatic reduction detected spectrophotometrically and by electron spin resonance spectroscopy."( The reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells: free radical formation and NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase) activity.
Fisher, GR; Gutierrez, PL, 1991
)
1.3
"Diaziquone is an effective chemotherapeutic agent for retinoblastoma in the xenograft model, and may have applications in clinical management."( Comparison of cyclophosphamide and diaziquone in a retinoblastoma xenograft model.
Reed, C; Tobias, V; White, L, 1989
)
1.28
"The diaziquone semiquinone is a stable free radical that exhibits a characteristic 5-line electron spin resonance (ESR) spectrum."( Diaziquone as a potential agent for photoirradiation therapy: formation of the semiquinone and hydroxyl radicals by visible light.
Gutierrez, PL; Mossoba, MM, 1985
)
2.19
"Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models. "( Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986
)
1.98
"Diaziquone (AZQ) is a quinone-containing alkylating agent undergoing trials as an antitumor drug. "( The influence of ascorbic acid on the free-radical metabolism of xenobiotics: the example of diaziquone.
Gutierrez, PL, 1988
)
1.94
"Diaziquone (AZQ) is a synthetic quinone with considerable activity against L1210 leukemia and potent myelosuppressive activity in man. "( Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial.
Lyman, GH; Raney, M; Vogler, WR, 1987
)
2.04
"Diaziquone (AZQ) is a lipophilic alkylating agent which crosses the blood-brain barrier and has marked antitumor activity in a broad spectrum of murine tumor systems. "( A phase II trial of diaziquone in patients with head and neck cancer.
Becker, M; Bender, JF; Grillo-Lopez, AJ; Muñiz, F; Neidhart, JA; Vélez-García, E, 1987
)
2.04
"Diaziquone (AZQ) is a benzoquinone derivative exhibiting significant effects against CNS tumors. "( Pharmacokinetics of diaziquone after three different dosage regimens.
Bjornsson, TD; Falletta, JM; Friedman, HS; Schneider, D; Schold, SC, 1985
)
2.04

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic behavior of intrathecally administered AZQ was characterized by biexponential disappearance from ventricular CSF, with mean half-lives of 18."( Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.
Balis, FM; Berg, SL; Doherty, K; Gillespie, A; Holcenberg, J; Murphy, RF; Reaman, G; Sato, J; Steinherz, P; Zimm, S, 1992
)
0.53
" In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40."( Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Ali-Osman, F; Dougherty, D; Giblin, J; Rosenblum, ML, 1987
)
0.27
" The average elimination half-life was 37."( Pharmacokinetics of diaziquone after three different dosage regimens.
Bjornsson, TD; Falletta, JM; Friedman, HS; Schneider, D; Schold, SC, 1985
)
0.59
" Plasma decay curves could be fitted to a two-compartment open model of drug disappearance with a dose-independent terminal half-life of 33."( Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Cordes, RS; Howser, DM; Ihde, DC; Kelley, JA; Schilsky, RL; Young, RC, 1982
)
0.26

Compound-Compound Interactions

Diaziquone (NSC 182986) alone and in combination with other antineoplastic drugs to treat six human glioma and one human medulloblastoma tumor lines growing s.

ExcerptReferenceRelevance
" At our institution, we are currently testing the efficacy and toxicity of regimens in which cytarabine or diaziquone are administered in combination with Bu and Cy."( New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
Devine, SM; Geller, RB; Holland, HK; Saral, R; Wingard, JR, 1993
)
0.79

Dosage Studied

Diaziquone demonstrates a very steep dose-response relationship. For phase II trials the recommended dosage of Diaziquone given by this schedule is 18 mg/M2/week X 4 for patients with a solid tumor.

ExcerptRelevanceReference
" After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays."( Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
Burger, P; Castleberry, RP; Kamen, B; Krischer, JP; Norris, D; Ragab, AH; Starling, K; Steuber, CP; Toledano, S, 1990
)
0.28
" Sufficient numbers of patients with osteosarcoma, neuroblastoma, and Wilms' tumor were evaluable to demonstrate inactivity of this dosing regimen in these tumor types."( A phase II study of diaziquone in children with recurrent or progressive solid tumors. Report from the Childrens Cancer Study Group.
Ettinger, LJ; Hammond, GD; Krailo, MD; Krivit, WA; Ru, N; Ruccione, KS, 1990
)
0.6
" For phase II trials the recommended dosage of Diaziquone given by this schedule is 18 mg/M2/week X 4 for patients with a solid tumor, and is 30 mg/M2/week X 4 for children with acute leukemia."( Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.
Bell, B; Castleberry, R; Cushing, B; Falletta, JM; Krance, RA; Lauer, S; Mahoney, DH, 1990
)
0.85
" The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination."( Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA, 1990
)
0.87
" The most active compounds, benzenesulfonate 4, p-toluenesulfonate 5, p-methoxybenzenesulfonate 7,8-quinolinesulfonate 17, and 2-thiophenesulfonate 20, in the aromatic sulfonate series, at their optimum daily dosage level of 25 mg/kg X 6, produced 100%, 90%, 75%, 80%, and 100% 50-day survivors, respectively, of L1210 tumor-bearing mice."( Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
Cosby, LA; Lin, TS; Sartorelli, AC; Xu, SP; Zhu, LY, 1989
)
0.28
" Our data suggest that this agent at the schedule and dosage used is of no benefit in pretreated breast cancer patients."( Treatment of metastatic breast cancer with AZQ: a phase II trial.
Haas, C; Martino, S; Ratanatharathorn, V; Samal, BA; Singhakowinta, A, 1988
)
0.27
" Even with this dosage reduction, myelosuppression (especially thrombocytopenia) was again the dose-limiting toxicity with 25% of patients experiencing granulocyte and platelet nadirs below 1000/mm3 and 50,000/mm3 respectively."( A phase II trial of diaziquone in patients with head and neck cancer.
Becker, M; Bender, JF; Grillo-Lopez, AJ; Muñiz, F; Neidhart, JA; Vélez-García, E, 1987
)
0.6
" Dosage adjustments were made according to leucocyte and platelet nadirs."( Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.
Grillo-Lopez, AJ; Jacquillat, C; Maral, J; Mashaly, P; Pertuiset, BF; Poisson, M; Weil, M, 1985
)
0.58
"5, 5:95 (v/v), was administered iv to mice at a dosage of 6 mg/kg (18 mg/m2)."( The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Bachur, NR; Collins, JM; Egorin, MJ; Lerner, BD; Spiegel, JF,
)
0.36
" Diaziquone demonstrates a very steep dose-response relationship."( Diaziquone (AZQ).
Bender, JF; Grillo-Lopez, AJ; Posada, JG, 1983
)
2.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
aziridines
enamineAn amine RNR'R'' where R has a double bond adjacent to the amine nitrogen.
1,4-benzoquinonesAny member of the class of benzoquinones that is 1,4-benzoquinone or its C-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID1144879Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 0.78 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144890Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 8 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144883Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as mouse survival at 1 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144855Antitumor activity against mouse LLC cells allografted in mouse assessed as change in body weight at 4 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1144869Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 0.78 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144836Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144857Antitumor activity against mouse LLC cells allografted in mouse assessed as change in body weight at 1 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID19922E1/2 for the half-wave potential at pH=7.0 in V571996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144893Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as cure rate at 2 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 991976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144859Therapeutic ratio, ratio of highest active dose to lowest active for antitumor activity against in ip dosed mouse allografted with mouse P388 cells1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144882Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as mouse survival at 2 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144891Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 0.5 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144880Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 0.39 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144827Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 1.3 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID21056Electrochemically observed pKa (pKred) of aziridines1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144885Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as mouse survival at 0.5 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144822Toxicity in mouse allografted with mouse L1210 cells at 12.5 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144888Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 2 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1144851Antitumor activity against mouse B16 cells allografted in mouse assessed as change in body weight at 0.78 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID94809In vitro cytotoxicity tested against human chronic leukemia K562 cells1997Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3
Cross-linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity.
AID1144837Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 1.56 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID97909log 1/ID75 for the in vitro clonogenic L1210 assay with ID75 in umol/L1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144841Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 1.56 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144852Toxicity in mouse allografted with mouse LLC cells at 4 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144856Antitumor activity against mouse LLC cells allografted in mouse assessed as change in body weight at 2 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144846Antitumor activity against mouse B16 cells allografted in mouse assessed as mouse survival at 1.56 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID136682Survival of mice bearing B16 melanoma cells greater than 50 days when treated with a dose of 3 mg/Kg administered intraperitoneally; tested in 5 mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID67600Tested for 50% inhibition against EMT-6 murine mammary carcinoma cell under normal oxygenated condition1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
AID1144820Antitumor activity against mouse L1210 cells allografted in ip dosed mouse at optimum dose administered qd on day 1, 5 and 9 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144860Therapeutic ratio, ratio of highest active dose to lowest active for antitumor activity against in ip dosed mouse allografted with mouse B16 cells1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144862Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 6.25 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1144894Therapeutic ratio in ip dosed mouse allografted with mouse ependymoblastoma cells1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID55494DNA cross link ratio at pH=5.0 and 50 umol/L compound1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144861Therapeutic ratio, ratio of highest active dose to lowest active for antitumor activity against in ip dosed mouse allografted with mouse LLC cells1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID97908log 1/D125 for the dose (mmol/kg) to give 125%T/C ratio (L1210) in vivo1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144867Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 3.12 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144878Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 1.56 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID19832Partition coefficient (logP)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144847Antitumor activity against mouse B16 cells allografted in mouse assessed as mouse survival at 0.78 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144819Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as optimum dose administered qd on day 1, 5 and 91976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144874Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 0.78 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID477847Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1144881Toxicity in mouse allografted with mouse ependymoblastoma cells at 8 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID128396Average change in weight in mice bearing the B16 Melanoma, when compound(3 mg/kg) was administered beginning 24 hr after tumor implantation, daily once for 6 consecutive days.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID1144843Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1144887Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 4 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144876Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 6.25 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID128402Average change in weight in mice bearing the L1210 Leukemia, when compound (3 mg/kg) was administered beginning 24 hr after tumor implantation, daily once for 6 consecutive days.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1144892Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 0.25 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID477848Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1144821Aqueous solubility of the compound1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144824Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144832Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 4.6 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144839Toxicity in mouse allografted with mouse P388 cells at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144829Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 12.5 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144849Antitumor activity against mouse B16 cells allografted in mouse assessed as change in body weight at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144875Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 0.39 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID228716log 1/anion production.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144840Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144889Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as change in body weight at 1 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID228714log KGSH for the rate k of glutathione (GSH) consumption in 1/s1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144868Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 1.56 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID228715log 1/LD50 for LD50 (mmol/kg)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1144871Toxicity in mouse allografted with mouse ependymoblastoma cells at 4 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144823Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID19838Partition coefficient (logP)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144863Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 3.12 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID18769Observed rate of hydrolysis (logKobs) (pH=4.0)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144864Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 1.56 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID128541The ratio of the survival time of treated to control animals x 100 in mice bearing B16 Melanoma, when compound (3 mg/kg) was administered intraperitoneally1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID1144835Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 0.88 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1144830Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID38961log 1/D125 or the dose (mmol/kg) to give 125%T/C ratio (B16) in vivo1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1144838Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 0.78 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144850Antitumor activity against mouse B16 cells allografted in mouse assessed as change in body weight at 1.56 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID477849Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1144833Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 2 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144866Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 6.25 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1144858Therapeutic ratio, ratio of highest active dose to lowest active for antitumor activity against in ip dosed mouse allografted with mouse L1210 cells1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID477850Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID477846Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID19426HPLC capacity factor (logK)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID1144845Antitumor activity against mouse B16 cells allografted in mouse assessed as mouse survival at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144877Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 3.12 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID136676Number of mice survived for a period of greater than 50 days when a dose of 3 mg/Kg is administered intraperitoneally; tested in 5 mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID477845Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Cytotoxic activities of several geranyl-substituted flavanones.
AID128691The ratio of the survival time of treated to control animals x 100 in mice bearing L1210 leukemia, when compound (3 mg/kg) was administered intraperitoneally1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents.
AID1144854Antitumor activity against mouse LLC cells allografted in mouse assessed as mouse survival at 1 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144828Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 0.88 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144831Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 3.12 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144825Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 4.6 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1144834Antitumor activity against mouse L1210 cells allografted in mouse assessed as change in body weight at 1.3 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1144865Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 0.78 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144872Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 3.12 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144842Antitumor activity against mouse P388 cells allografted in mouse assessed as change in body weight at 0.78 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID67602Tested for 90% inhibition against EMT-6 murine mammary carcinoma cell under normal oxygenated condition1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1144853Antitumor activity against mouse LLC cells allografted in mouse assessed as mouse survival at 2 mg/kg, ip qd administered from day 5 to 15 post sc tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144826Antitumor activity against mouse L1210 cells allografted in mouse assessed as mouse survival at 2 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144870Toxicity in mouse allografted with mouse P388 cells at 6.25 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID67601Tested for 90% inhibition against EMT-6 murine mammary carcinoma cell under hypoxia condition1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
AID1144884Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as mouse survival at 4 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144848Antitumor activity against mouse B16 cells allografted in mouse assessed as change in body weight at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation measured on day 5 relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID72099log 1/MIC for fungi in mmol/L1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID67599Tested for 50% inhibition against EMT-6 murine mammary carcinoma cell under hypoxia condition1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
AID1144844Toxicity in mouse allografted with mouse B16 cells at 6.25 mg/kg, ip qd administered from day 1 to 9 post ip tumor-implantation1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1144886Antitumor activity against mouse ependymoblastoma cells allografted in mouse assessed as mouse survival at 0.25 mg/kg, ip qd administered from day 1 to 5 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1144873Antitumor activity against mouse P388 cells allografted in mouse assessed as mouse survival at 1.56 mg/kg, ip qd administered from day 1 to 9 post intracerebral tumor-implantation relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (194)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990120 (61.86)18.7374
1990's55 (28.35)18.2507
2000's12 (6.19)29.6817
2010's2 (1.03)24.3611
2020's5 (2.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.47 (24.57)
Research Supply Index5.42 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (10.78%)5.53%
Reviews15 (7.35%)6.00%
Case Studies3 (1.47%)4.05%
Observational0 (0.00%)0.25%
Other164 (80.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]